PCI Ventures portfolio company OmicPath AI was recently published in Nature. OmnicPath AI specializes in developing an end-to-end workflow that integrates Spatial Transcriptomics (ST) data and high-resolution histology images to predict spatial gene expression and characterize tissue architecture with super-resolution.
The company was founded by Mingyao Li, PhD, Professor of Biostatistics in Biostatistics and Epidemiology, and David Zhang, PhD, machine learning scientist and researcher in Li’s lab.
OmnicPath AI has made significant advancements in enhancing gene expression resolution and enabling prediction in tissue sections with only histology images.
Read the Nature Biotechnology publication here.